Payment overview · 2025
General Payments
$570.69
21 reported records · 6 companies
Healthcare provider profile · identity verified
Debabrata Sen, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BROOKLYN, NY · NPI 1629012539
Verified facts
What the public records show
CMS Open Payments records show Debabrata Sen, MD received $570.69 in general payments during 2025 across 21 reported records.
Novartis Pharmaceuticals Corporation accounted for 38.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Entresto, Farxiga, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $219.79 | 38.5% | 8 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $195.03 | 34.2% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $87.93 | 15.4% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $31.43 | 5.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $22.33 | 3.9% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.18 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $570.69 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $195.03 | 6 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $159.17 | 5 | 2025 |
Source payment records
|
|||||
| AVYCAZ Normalized: avycaz |
Drug | ABBVIE INC. | $87.93 | 4 | 2025 |
Source payment records
|
|||||
| DALVANCE Normalized: dalvance |
Drug | ABBVIE INC. | $87.93 | 4 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $60.62 | 3 | 2025 |
Source payment records
|
|||||
| TEFLARO Normalized: teflaro |
Drug | ABBVIE INC. | $44.92 | 2 | 2025 |
Source payment records
|
|||||
| CARDIOMEMS Normalized: cardiomems |
Device | Abbott Laboratories | $31.43 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $22.33 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.18 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.18 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ENTRESTO entresto |
2025 | Entresto | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 80 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 42 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
80 | 37 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 371 | 134 |
| Atorvastatin Calcium | Atorvastatin Calcium | 355 | 146 |
| Losartan Potassium | Losartan Potassium | 318 | 121 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 290 | 107 |
| Metformin Hcl | Metformin Hcl | 192 | 74 |
| Nifedipine Er | Nifedipine | 191 | 79 |
| Gabapentin | Gabapentin | 182 | 77 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 172 | 55 |
| Metoprolol Succinate | Metoprolol Succinate | 156 | 60 |
| Diclofenac Sodium Er | Diclofenac Sodium | 144 | suppressed |
| Carvedilol | Carvedilol | 139 | 56 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 135 | 39 |
| Enalapril Maleate | Enalapril Maleate | 135 | 49 |
| Tamsulosin Hcl | Tamsulosin Hcl | 134 | 55 |
| Januvia | Sitagliptin Phosphate | 128 | 44 |
| Pantoprazole Sodium | Pantoprazole Sodium | 122 | 68 |
| Furosemide | Furosemide | 115 | 38 |
| Eliquis | Apixaban | 94 | 32 |
| Alendronate Sodium | Alendronate Sodium | 86 | 34 |
| Farxiga | Dapagliflozin Propanediol | 80 | 37 |
| Fluticasone Propionate | Fluticasone Propionate | 79 | 40 |
| Ezetimibe | Ezetimibe | 75 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 74 | 27 |
| Famotidine | Famotidine | 65 | 27 |
| Prednisone | Prednisone | 62 | 46 |
| Clopidogrel | Clopidogrel Bisulfate | 61 | 19 |
| Levothyroxine Sodium | Levothyroxine Sodium | 61 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 58 | 26 |
| Omeprazole | Omeprazole | 52 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 48 | 19 |
| Calcitriol | Calcitriol | 46 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 46 | 14 |
| Lactulose | Lactulose | 44 | 11 |
| Ozempic | Semaglutide | 42 | suppressed |
| Spironolactone | Spironolactone | 41 | 28 |
| Finasteride | Finasteride | 40 | 19 |
| Glipizide | Glipizide | 40 | 15 |
| Valsartan | Valsartan | 40 | suppressed |
| Allopurinol | Allopurinol | 39 | 12 |
| Azithromycin | Azithromycin | 38 | 36 |
| Latanoprost | Latanoprost | 37 | 18 |
| Breo Ellipta | Fluticasone/Vilanterol | 36 | suppressed |
| Atenolol | Atenolol | 35 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 35 | 15 |
| Jardiance | Empagliflozin | 34 | 14 |
| Glipizide Er | Glipizide | 33 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 32 | 12 |
| Entresto | Sacubitril/Valsartan | 31 | suppressed |
| Xarelto | Rivaroxaban | 30 | suppressed |
| Colchicine | Colchicine | 29 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | 17 |
| Labetalol Hcl | Labetalol Hcl | 28 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 26 |
| Clobetasol Propionate | Clobetasol Propionate | 26 | 11 |
| Levetiracetam | Levetiracetam | 26 | 13 |
| Montelukast Sodium | Montelukast Sodium | 26 | 13 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 25 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 12 |
| Clotrimazole | Clotrimazole | 24 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Chlorthalidone | Chlorthalidone | 23 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 23 | 18 |
| Ibuprofen | Ibuprofen | 23 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 23 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 22 | 13 |
| Naproxen Sodium | Naproxen Sodium | 22 | suppressed |
| Tradjenta | Linagliptin | 22 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 21 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 21 | 17 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | 11 |
| Potassium Chloride | Potassium Chloride | 20 | 11 |
| Lisinopril | Lisinopril | 19 | suppressed |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 18 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 18 | 13 |
| Levofloxacin | Levofloxacin | 18 | 17 |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Calcium Acetate | Calcium Acetate | 17 | suppressed |
| Folic Acid | Folic Acid | 17 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 17 | suppressed |
| Simvastatin | Simvastatin | 17 | suppressed |
| Trulicity | Dulaglutide | 17 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 16 | suppressed |
| Cilostazol | Cilostazol | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Meloxicam | Meloxicam | 15 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 15 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 15 | 12 |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 14 | suppressed |
| Fluocinonide | Fluocinonide | 14 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 13 | 13 |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $570.69 · 21 records | Novartis Pharmaceuticals Corporation | AVYCAZ, CARDIOMEMS, DALVANCE, ENTRESTO, FARXIGA, LEQVIO, LifeVest, Ozempic, Rybelsus, TEFLARO | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Entresto play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error